The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy

ConditionGastric Carcinoma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-85

SponsorJichao Qin

About this trial

This study aims to examine the predictive value of metastatic gastric mesenteries, which contains metastatic lymph node, in 6 gastric mesenteries; and importantly, to further evaluate the relationship between the number of metastatic gastric mesenteries and prognosis in the gastric cancer patients who received D2+complete mesogastric excision (CME).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged older than 18 years and younger than 85 years

Primary gastric adenocarcinoma confirmed by preoperative pathology result

cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition

Patients who received gastrectomy with D2 lymphadenectomy plus complete mesogastric excision

Disqualifiers

Negative preoperative biopsy

Too late tumour stage or metastasis (cT4b/M1)

BMI>30 kg/m2

Total gastrectomy or proximal gastrectomy

Trial population

Patients who met the above inclusion and exclusion criteria

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

400 Participants

are grouped into 1 trial group

Group A: D2+CME surgery for gastric cancer

Trial outcomes

Primary outcomes

overall survival

Prognostic impact of lymph node-positive mesenteric count in gastric cancer

Time frame

through study completion, an average of 3 year

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Jichao Qin

Lead sponsor

First Affiliated Hospital of Zhejiang University

Sponsor institution

Zhejiang University

Collaborator

Source ClinicalTrials.gov

Apply now